Hrt Financial LP Allakos Inc. Transaction History

Hrt Financial LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.62 - $1.5 $7,196 - $17,410	11,607 New	11,607 $14,000
Q2 2024 Aug 12, 2024	BUY	$1.0 - $1.45 $29,328 - $42,525	29,328 New	29,328 $29,000
Q3 2023 Nov 13, 2023	BUY	$2.13 - $5.55 $155,592 - $405,416	73,048 New	73,048 $165,000
Q1 2023 May 12, 2023	BUY	$4.3 - $8.27 $1.29 Million - $2.48 Million	300,043 New	300,043 $1.34 Million
Q2 2022 Aug 12, 2022	SELL	$2.6 - $6.14 $35,232 - $83,203	-13,551 Reduced 9.74%	125,521 $392,000
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $629,427 - $1.22 Million	123,903 Added 816.82%	139,072 $792,000
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $129,694 - $1.7 Million	15,169 New	15,169 $148,000
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $229,612 - $481,985	-5,161 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$66.49 - $137.73 $140,692 - $291,436	-2,116 Reduced 29.08%	5,161 $492,000
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $225,587 - $652,965	7,277 New	7,277 $572,000

52.3M

71.5K

19.8K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $28M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.